TGCA helps organizations across the care continuum navigate the complexities of molecular therapies.

TGCA is the pre-eminent consulting firm specifically focused on disease-modifying molecular therapeutics.

We provide unparalleled, unbiased science-based knowledge backed by years of industry experience. Our strength lies in our unique ability to understand the continuously evolving science at its core, distill it, and create resources that provide both definition and knowledge.

Our Values

Patient Driven

We seek out the patient perspective in all aspects of our business.

Research Oriented

We go beyond the printed material or the clinical trial data.

Education Centric

We are passionate about increasing the knowledge and understanding of molecular therapies across the healthcare continuum.


We listen and combine multiple points of view to arrive at unique solutions.

Future Focused

We exhaustively study what is happening within drug development to understand future trends.

It’s in our DNA.

We live and breathe all things genetic medicine. TGCA is more than our name, it represents the building blocks of the genetic code – thymine (T), guanine (G), cytosine (C), and adenine (A) – which form one of nature’s most elegant structures, the DNA double-helix.

TGCA combines 20 years of molecular biology research with 25 years of business experience.

Our expertise lies in the ability to understand the implications these cutting-edge therapies have on the patient journey, now and in the future.

Together, we can enhance your patient-focused care, mitigate risk, invest in proper solutions, and create a foundation that generates success for years to come.

Check out publications from our Chief Science Officer, Dr. Rebecca L. Bigler.

Let’s Talk.

  • This field is for validation purposes and should be left unchanged.